Full text is available at the source.
Abstract
The optimized charcoal depletion improved assay drug tolerance by approximately 100-fold.
- Peptide-based therapeutics like GLP-1 analogs are important for treating metabolic diseases.
- Assessing immunogenicity during clinical development is crucial for understanding safety and efficacy.
- A sample pretreatment strategy using activated charcoal was developed to reduce drug interference.
- The method enabled the detection of neutralizing anti-drug antibodies in clinical samples.
- This approach could be widely applicable to other peptide therapeutics facing drug tolerance issues.
Simplified